Status of PI3K inhibition and biomarker development in cancer therapeutics

B. Markman, F. Atzori, J. Pérez-García, J. Tabernero, J. Baselga

Research output: Contribution to journalReview articleResearchpeer-review

135 Citations (Scopus)


The phosphatidylinositol 3-kinase (PI3K) signalling pathway is integral to diverse cellular functions, including cellular proliferation, differentiation and survival. The 'phosphate and tensin homologue deleted from chromosome 10' (PTEN) tumor suppressor gene plays a critical role as a negative regulator of this pathway. An array of genetic mutations and amplifications has been described affecting key components of this pathway, with implications not only for tumorigenesis but also for resistance to some classic cytotoxics and targeted agents. Emerging preclinical research has significantly advanced our understanding of the PI3K pathway and its complex machinations and interactions. This knowledge has enabled the evolution of rationally designed drugs targeting elements of this pathway. It is important that the development of suitable biomarkers continues in parallel to optimize use of these agents. A new generation of PI3K inhibitors is now entering early clinical trials, with much anticipation that they will add to the growing armamentarium of targeted cancer therapeutics. © The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email:
Original languageEnglish
Pages (from-to)683-691
JournalAnnals of Oncology
Issue number4
Publication statusPublished - 27 Aug 2009


  • Biomarker
  • Clinical trials
  • mTOR inhibitor
  • PI3K inhibitor
  • PI3K pathway
  • PTEN


Dive into the research topics of 'Status of PI3K inhibition and biomarker development in cancer therapeutics'. Together they form a unique fingerprint.

Cite this